ArticleBMC infectious diseases2026
Detection of hypervirulence genes in carbapenem resistant Klebsiella pneumoniae from cancer patients at a tertiary referral hospital in Nepal.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCarbapenem-resistant Klebsiella pneumoniae (CRKP) are a serious public health threat and is linked to high mortality, particularly in immunocompromised and critically ill patients. In addition, hyper-virulent K. pneumoniae (hvKP) variants contributing to severe clinical outcomes in cancer patients. This study aims to identify carbapenem-resistant K. pneumoniae isolates from cancer patients and detect associated hypervirulence genes.
methodsClinical specimens were collected from cancer patients and processed for bacterial isolation and identification by conventional method. The antibiotic susceptibility testing was performed using Kirby Bauer disk diffusion method following CLSI guideline. All carbapenem-resistant K. pneumoniae isolates were further analyzed for carbapenemase production using the modified carbapenem inactivation method (mCIM) and metallo-β-lactamase (MBL) production using the EDTA-modified carbapenem inactivation method (eCIM). The presence of carbapenemase and hypervirulence encoding genes in CRKP were confirmed by polymerase chain reaction (PCR). All data were analyzed using SPSS. The chi-square test was applied to assess associations, and a p-value < 0.05 was considered statistically significant at a 95% confidence interval.
resultsOut of 4273 samples, bacterial growth was observed in 23% (987/4273) with a total of 1016 bacterial isolates, including polymicrobial growth. A total of 23.7% (241/1016) of K. pneumoniae isolates were retrieved from 241 cancer patients. Carbapenem-resistant K. pneumoniae (CRKP) isolates were detect in 53.5% (129/241), with 38% (49/129) of blaNDM−1 as predominant carbapenemase gene. Among hypervirulence markers, iucA (66.7%, 86/129) was the most prevalent. Co-occurrence of carbapenem resistance genes and hypervirulence genes was detected in 21% (27/129) among CRKP.
conclusionEffective intervention strategies are crucial to enhance the timely clinical recognition and optimal management of CRKP and hvKP infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.